Tanabe O, Kawano M, Tanaka H, Iwato K, Asaoku H, Ishikawa H, Nobuyoshi M, Hirano T, Kishimoto T, Kuramoto A
Department of Internal Medicine, Hiroshima University, Japan.
Am J Hematol. 1989 Aug;31(4):258-62. doi: 10.1002/ajh.2830310408.
Human myeloma cells were highly purified from bone marrow aspirates of 21 patients with advanced immunoglobulin G (IgG)-type multiple myeloma. B-cell stimulatory factor 2 (BSF-2)/interleukin-6 (IL-6) was originally characterized as a cytokine that can enhance immunoglobulin secretion from activated normal B cells and increase the expression of secretory-type Ig mRNA in these B cells, but that does not augment proliferation of activated B cells. However, recombinant IL-6 (rIL-6) could not enhance M-protein (IgG) secretion in freshly isolated myeloma cells in vitro but could augment proliferation of myeloma cells, although myeloma cells constitutively expressed IL-6 receptors. Furthermore, expression of secretory-type IgG (gamma-chain) mRNA in myeloma cells was not changed in the presence of IL-6. These results show that IL-6 is not an enhancing factor in Ig secretion from myeloma cells, and thus signal transduction through IL-6 in myeloma cells may be altered as opposed to activated B cells.
从21例晚期免疫球蛋白G（IgG）型多发性骨髓瘤患者的骨髓穿刺物中高度纯化出人骨髓瘤细胞。B细胞刺激因子2（BSF-2）/白细胞介素-6（IL-6）最初被鉴定为一种细胞因子，它可以增强活化的正常B细胞的免疫球蛋白分泌，并增加这些B细胞中分泌型Ig mRNA的表达，但不会增强活化B细胞的增殖。然而，重组IL-6（rIL-6）在体外不能增强新鲜分离的骨髓瘤细胞中M蛋白（IgG）的分泌，但可以增强骨髓瘤细胞的增殖，尽管骨髓瘤细胞组成性表达IL-6受体。此外，在IL-6存在的情况下，骨髓瘤细胞中分泌型IgG（γ链）mRNA的表达没有改变。这些结果表明，IL-6不是骨髓瘤细胞Ig分泌的增强因子，因此与活化B细胞相反，骨髓瘤细胞中通过IL-6的信号转导可能发生了改变。
